Integrin inhibitors as a therapeutic agent for ovarian cancer
about
Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer CellsFlow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules.Ovarian tumor attachment, invasion, and vascularization reflect unique microenvironments in the peritoneum: insights from xenograft and mathematical models.Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.Targeting signaling pathways in epithelial ovarian cancer.Genomic and transcriptomic plasticity in treatment-naive ovarian cancerNovel approach for the detection of intraperitoneal micrometastasis using an ovarian cancer mouse model.CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies.Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors.Identification of Pharmacologically Tractable Protein Complexes in Cancer Using the R-Based Network Clustering and Visualization Program MCODER.Tumour but not stromal expression of β3 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer.An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients.Collagen triple helix repeat containing 1 (CTHRC1) activates Integrin β3/FAK signaling and promotes metastasis in ovarian cancer.Suppression of focal adhesion formation may account for the suppression of cell migration, invasion and growth of non-small cell lung cancer cells following treatment with polyisoprenylated cysteinyl amide inhibitors.
P2860
Q26738643-8123237D-FE86-497F-ADD0-636BF6D23127Q30446755-5F932B6D-6D55-4D1D-8ADA-59E371EB75E8Q30539859-BE523994-0EDD-4A2F-BE0D-C170CEE64DD7Q34311697-B900C1CE-651B-4213-9C35-0A3DF8F36DCAQ36180735-319E4AC9-F8B4-4257-BF7D-AA13A07E4AFCQ36754457-68F0D7E5-C1E5-4CB1-9D48-AAF7E034BE57Q36913614-E4AF616D-2842-4D99-9B6B-26DDF43F02D1Q37550198-BCBAA9D0-F563-4978-A076-B4B60E4893A3Q37604850-CF6F1730-BD03-4948-81D9-4F184858F31CQ37611842-6FC7FD8B-7AA0-40A7-8618-C7D682BFCBE3Q38161726-6BE4F842-014F-47EC-900B-CD95964D6CC2Q38687169-E755D77F-0194-4BFE-875D-808F954E1213Q38937289-AB7EEE84-BD1B-4C49-A668-73E6F41B6380Q41593205-47CB2FE5-321D-4108-988E-5A2C9DD1F6BDQ42375241-2179D858-2BC1-400A-8897-D8090CD6AB66Q55182324-EF8C5C7A-6DAE-49BF-A66F-2C43817F2C40
P2860
Integrin inhibitors as a therapeutic agent for ovarian cancer
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Integrin inhibitors as a therapeutic agent for ovarian cancer
@ast
Integrin inhibitors as a therapeutic agent for ovarian cancer
@en
type
label
Integrin inhibitors as a therapeutic agent for ovarian cancer
@ast
Integrin inhibitors as a therapeutic agent for ovarian cancer
@en
prefLabel
Integrin inhibitors as a therapeutic agent for ovarian cancer
@ast
Integrin inhibitors as a therapeutic agent for ovarian cancer
@en
P2093
P2860
P356
P1433
P1476
Integrin inhibitors as a therapeutic agent for ovarian cancer
@en
P2093
Chifumi Ohyagi-Hara
Ken-Ichirou Morishige
Kenjiro Sawada
Tadashi Kimura
P2860
P304
P356
10.1155/2012/915140
P577
2011-12-25T00:00:00Z